LEIDEN, The Netherlands--(BUSINESS WIRE)--Azafaros B.V. today announced that the first patient has been enrolled into its Phase 2 RAINBOW study (NCT05758922). The clinical trial is being conducted in ...

A rainbow crosswalk in Columbus, Ohio, that was part of a federal road safety study has been vandalized. The defacement comes at a time when the current presidential administration has claimed that ...

LEIDEN, Netherlands--(BUSINESS WIRE)--Azafaros has announced that data from the ongoing double-blind, placebo-controlled Phase 2 RAINBOW study investigating its lead asset, nizubaglustat in patients ...

Major milestone reached in bringing new treatment options to patients and their families. Leiden, The Netherlands, March 12, 2024 – Azafaros B.V. today announced the completion of its 12-week Phase 2 ...

Topline data from the study, expected for mid-2024, will support two pivotal Phase 3 trials in GM1 and GM2 Gangliosidoses and Niemann-Pick disease type C Number of patients recruited into the RAINBOW ...